首页> 外文期刊>Disease Management >'Personalized' Medicine: Changing the Practice and Economics of Healthcare
【24h】

'Personalized' Medicine: Changing the Practice and Economics of Healthcare

机译:“个性化”医学:改变医疗保健的实践和经济学

获取原文
获取原文并翻译 | 示例
           

摘要

Today the pharmaceutical industry Operates under the "blockbuster" rule, whereby revenue from the sale of "blockbuster" drugs provides most of the funding for new drug development. With the average cost of bringing a new drug to market hovering at $880 million, the "blockbuster" has been the cornerstone of the market. The problem with this strategy is that it implies "one size fits all" and doesn't take subtle genetic variations into account. We have learned that gene variations ultimately determine a drug's safety, efficacy and dose, and we are moving toward a time when all things will be unequal.
机译:如今,制药行业在“重磅炸弹”规则下运作,通过销售“重磅炸弹”药物获得的收入为新药开发提供了大部分资金。随着将新药推向市场的平均成本徘徊在8.8亿美元,“重磅炸弹”一直是市场的基石。这种策略的问题在于,它暗示着“一个大小适合所有人”,并且没有考虑到微妙的遗传变异。我们已经了解到基因变异最终决定了药物的安全性,功效和剂量,并且我们正朝着万物不平等的时代迈进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号